Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 25;7(6):102183.
doi: 10.1016/j.rpth.2023.102183. eCollection 2023 Aug.

Progestin-only contraception is first line for sickle cell disease: a comment on "Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias."

Lydia H Pecker  1   2 , Anne Burke  2   3 , Michael B Streiff  1 , Sophie Lanzkron  1 , Rakhi P Naik  1
Affiliations

Progestin-only contraception is first line for sickle cell disease: a comment on "Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias."

Lydia H Pecker et al. Res Pract Thromb Haemost. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
The 2016 Centers for Disease Control and Prevention’s Medical Eligibility Criteria for Contraception Guideline approves wide use of estrogen-containing contraception for sickle cell disease (SCD). Subsequent rows illustrate how these recommendations would change if SCD was recognized as a thrombogenic mutation, how the presence of gallbladder disease and other common SCD comorbidities are considered by the Guideline, and how the consideration given to other conditions, such as rheumatoid arthritis, lupus, and cystic fibrosis were not extended to SCD, which is considered a “sub-condition,” obfuscating disease complications that exacerbate high baseline thrombosis risks. Source: Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65:1–103. https://doi.org/10.15585/mmwr.rr6503a1
See this image and copyright information in PMC

References

    1. Baldwin M.K., Bannow B.S., Rosovsky R.P., Sokkary N., Srivaths L.V. Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias. Res Pract Thromb Haemost. 2023;7 doi: 10.1016/j.rpth.2023.100161. - DOI - PMC - PubMed
    1. Ogunsile F.J., Naik R., Lanzkron S. Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Rev Hematol. 2019;12:173–182. - PubMed
    1. Pecker L.H., Kuo K.H.M. Go the distance: reproductive health care for people with sickle cell disease. Hematol Oncol Clin North Am. 2022;36:1255–1270. - PMC - PubMed

LinkOut - more resources